A registry study of early TAVI devices finds that patients with Medtronic's CoreValve were more likely to have aortic regurgitation, but patients with Edwards Lifesciences' Sapien fared worse if they had aortic regurgitation.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1p4F2NX
Cap comentari:
Publica un comentari a l'entrada